SironRX Therapeutics Inc.
This article was originally published in Start Up
Executive Summary
SironRX Therapeutics Inc. is betting that a product encoding a protein naturally produced by the body in response to tissue injury, and known to recruit stem cells, can become a drug effective at healing wounds and preventing skin scarring. The start-up got rights to Stromal cell-Derived Factor-1 from Juventas Therapeutics and Cleveland Clinic.
You may also be interested in...
Juventas Moves Into Phase II With Funds From $22M Series B
Cleveland Clinic spinout Juventas Therapeutics raised $22 million that will help fund mid-stage studies of its adult stem cell treatment.
Start-Up Previews (09/2011)
This Month's Profile Group: Cartilage Repair: Opportunities In Motion-Preserving Orthopedics, features profiles of Articulinx, Carticept Medical and Orthox. Plus these Start-Ups Across Health Care: Ellipse Technologies, JDP Therapeutics, NuMe Health and SironRX Therapeutics.
Start-Up Previews (09/2011)
This Month's Profile Group: Cartilage Repair: Opportunities In Motion-Preserving Orthopedics, features profiles of Articulinx, Carticept Medical and Orthox. Plus these Start-Ups Across Health Care: Ellipse Technologies, JDP Therapeutics, NuMe Health and SironRX Therapeutics.